Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02682394|
Recruitment Status : Unknown
Verified September 2015 by Soroka University Medical Center.
Recruitment status was: Recruiting
First Posted : February 15, 2016
Last Update Posted : February 15, 2016
|Condition or disease|
|Cancer of Pancreas|
- Finding patients with pancreatic cancer (in all stages), before any treatment.
- Non invasively quantify fatty infiltration of pancreas using, MRI DIXON Scan in pancreatic cancer patient relatively to liver.
- Measuring cell-free blood DNA in those patients for evaluating the aggressiveness of the disease.
- Quantify the prognostic significance of pancreatic steatosis in comparison with clinical and pathological prognostic indexes used today.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients With Pancreatic Cancer|
|Study Start Date :||September 2015|
|Estimated Primary Completion Date :||September 2017|
|Estimated Study Completion Date :||October 2017|
- Percentage of fat in pancreas measured in the head, body and tail excluding the lesion area. [ Time Frame: at 24 hours before chemotherapy starting ]measuring Pancreatic Steatosis in patients with pancreatic cancer using MRI DIXON scan, at 24 hours before chemotherapy starting.
- Blood levels of free DNA [ Time Frame: The blood sample taken 15 minutes prior to MRI study, at time of IV access. ]Correlation of free DNA level and metastatic spread.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02682394
|Contact: Vladimir Borodetsky, MDfirstname.lastname@example.org|
|Contact: Irena Lazerev, MDemail@example.com|
|Soroka university medical center||Recruiting|
|Beer Sheva, Israel, =|
|Contact: Vladimir Borodetsky, MD +972547428882 firstname.lastname@example.org|
|Contact: Irina Lazerev, MD +972526226458 email@example.com|
|Principal Investigator: Alla Khashper, MD|
|Principal Investigator:||Alla Khashper, MD||Soroka University Medical Center|